Another previous study in HER2-positive breast cancer patients revealed the reduction of plasma citrate and isocitrate levels in patients who developed systolic heart failure at three months and six months after completion of doxorubicin and trastuzumab treatment [57]. The gene discussed is ERBB2; the disease is breast carcinoma.